Modulation of Cell Surface Markers on Nk-Like T Lymphocytes by Using Il-2, Il-7 or Il-12 in Vitro Stimulation

Zoll, B; Lefterova, Petja; Ebert, Oliver; Huhn, D.; Ruecker, Alexander von; Schmidt‐Wolf, Ingo G.H.

doi:10.1006/cyto.2000.0733

Cited by 30 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the studies use T cells cultured for 14 to 21 days. Cytokines such as IFN-γ, IL-1, IL-2, IL-7, IL-15, and IL-12 have been evaluated for their ability to promote the CIK generation [12,44-48]. According to the standard CIK culture condition, IFN-γ is added at the beginning of the culture and 24 h before the addition of anti-CD3 mAb and IL-2 [12].…”

Section: Improving Cik Therapy For Epithelial Cancermentioning

confidence: 99%

Cytokine-induced killer cells promote antitumor immunity

Jiang

2013

J Transl Med

127

View full text Add to dashboard Cite

The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer patients. Such antitumor cellular immune responses can be greatly enhanced by adoptive transfer of activated type 1 lymphocytes. Recently, adoptive cell therapy based on infusion of ex vivo expanded TILs has achieved substantial clinical success. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8 T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Preclinical studies of CIK cells in murine tumor models demonstrate significant antitumor effects against a number of hematopoietic and solid tumors. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with comparable malignancies. Enhancing the potency and specificity of CIK therapy via immunological and genetic engineering approaches and identifying robust biomarkers of response will significantly improve this therapy.

show abstract

Section: Improving Cik Therapy For Epithelial Cancermentioning

confidence: 99%

Cytokine-induced killer cells promote antitumor immunity

Jiang

2013

J Transl Med

127

View full text Add to dashboard Cite

show abstract

“…Particularly IL-12 was long thought to be the most promising anti-tumor cytokine due to its broad and potent anti-tumor effects in preclinical models [9, 10]. It was shown that for ex vivo expansion of CIK cells IL-2 or IL-12 show similar utility, while having different physiological roles [43, 44]. …”

Section: Introductionmentioning

confidence: 99%

IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy

Helms

Prescher

Cao

et al. 2010

Cancer Immunol Immunother

View full text Add to dashboard Cite

Cytokine-induced killer (CIK) cells are T cell derived ex vivo expanded cells with both NK and T cell properties. They exhibit potent anti-tumor efficacy against various malignancies in preclinical models and have proven safe and effective in clinical studies. We combined CIK cell adoptive immunotherapy with IL-12 cytokine immunotherapy in an immunocompetent preclinical breast cancer model. Combining CIK cells with IL-12 increased anti-tumor efficacy in vivo compared to either therapy alone. Combination led to full tumor remission and long-term protection in 75% of animals. IL-12 treatment sharply increased the anti-tumor efficacy of short-term cultured CIK cells that exhibited no therapeutic effect alone. Bioluminescence imaging based in vitro cytotoxicity and in vivo homing assays revealed that short-term cultured CIK cells exhibit full cytotoxicity in vitro, but display different tumor homing properties than fully expanded CIK cells in vivo. Our data suggest that short-term cultured CIK cells can be “educated” in vivo, producing fully expanded CIK cells upon IL-12 administration with anti-tumor efficacy in a mouse model. Our findings demonstrate the potential to improve current CIK cell-based immunotherapy by increasing efficacy and shortening ex vivo expansion time. This holds promise for a highly efficacious cancer therapy utilizing synergistic effects of cytokine and cellular immunotherapy.

show abstract

“…DCs, as the main powerful antigen-presenting cells in the human body, can induce antigen-specific cytotoxic T lymphocytes [14], affect the proliferation of B cells, and activate humoral immune responses [15]. The combination of CIK cells and DCs for the treatment of malignant tumors can relieve the immune incompetence of T cells in tumor patients and has a synergistic antitumor effect.…”

Section: Discussionmentioning

confidence: 99%

Curative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion

et al. 2016

View full text Add to dashboard Cite

BackgroundTo determine the effects of dendritic cells (DCs) and cytokine-induced killer (CIK) cells in patients with malignant pericardial effusion.Material/MethodsAll patients underwent pericardial puncture and indwelling catheter insertion. After pericardial drainage, the 16 patients in the treatment group received an infusion of 20 mL DCs and CIK cells (>1.0×1010 cells) and 500,000 U interleukin (IL)-2 for 3 successive days. The 15 control-group patients received 30 mg/m2 cisplatin and 500,000 U IL-2 for 3 successive days. The treatment effects were assessed using imaging data.ResultsThe total efficiency and complete remission rates were higher in the treatment group than in the control group at 4 weeks (total efficiency: 87.50% vs. 73.33%; complete remission: 62.50% vs. 46.67%) and 3 months after the treatment (total efficiency: 81.25% vs. 66.67%; complete remission: 50.00% vs. 40.00%; P<0.05 for all). In both groups, the Karnofsky scores for quality of life improved after treatment. However, the curative effects were better in the treatment group than in the control group (P<0.05). The following adverse reactions occurred: fever, 6 treatment-group patients and 3 control-group patients; chest pain, 2 treatment-group patients and 7 control-group patients; gastrointestinal reactions, 1 treatment-group patient and 6 control-group patients; and bone marrow suppression, 1 treatment-group patient and 5 control-group patients. The between-group differences in adverse reactions were significant (P<0.05).ConclusionsThe combination of DCs and CIK cells effectively treated malignant pericardial effusion, produced few side effects, and improved the patients’ quality of life.

show abstract

Modulation of Cell Surface Markers on Nk-Like T Lymphocytes by Using Il-2, Il-7 or Il-12 in Vitro Stimulation

Cited by 30 publications

References 14 publications

Cytokine-induced killer cells promote antitumor immunity

Cytokine-induced killer cells promote antitumor immunity

IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy

Curative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion

Contact Info

Product

Resources

About